Compare Cassava Sciences Inc (FLNA) vs Kraft Heinz Co (KHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Kraft Heinz Co — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while Kraft Heinz Co trades at $26.36 (market cap $30.18B). The key difference: Kraft Heinz Co is far larger — about 567.9× Cassava Sciences Inc's market cap, and Kraft Heinz Co pays a 6.29% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | KHC | |
|---|---|---|
Market Cap | $53.14M | $30.18B |
Sector | Health | Consumer Staples |
52-Week High | $4.64 | $28.94 |
52-Week Low | $1.09 | $21.21 |
Enterprise Value | -$33.43M | $47.22B |
Dividend Yield | — | 6.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Kraft Heinz (KHC) trades at $26.165, up 4.33% over the past session, with a bullish technical signal from moving averages. The stock shows mixed fundamentals with a negative net income margin of -23.05% in 2025 but has beaten EPS estimates for three consecutive quarters. Recent news highlights a global restructuring to accelerate growth and a $0.40 dividend payment scheduled for June 2026.
The outlook is cautious due to profitability challenges, though valuation metrics like P/B of 0.72 suggest potential undervaluation. Risks include execution of the new operating model and competitive pressures. Analyst consensus is predominantly Hold with a price target of $23.20, indicating limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →
